When was Olatec founded?

Olatec was founded in 2003 and raised its 1st funding round 20 years after it was founded.

Where is Olatec located?

Olatec is headquartered in New York City, United States.

How many employees does Olatec have?

As of Jun 30, 2026, the latest employee count at Olatec is 14.

Is Olatec a funded company?

Olatec is a funded company, having raised a total of $40M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 23, 2023.

When was the latest funding round of Olatec?

Olatec's latest funding was a $***** Grant (prize money) round on Mar 10, 2023, with participation from 1 investor.

Where does Olatec rank among its competitors?

Olatec ranks 44th amongst 310 active competitors, of which 113 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Trimtech Therapeutics, which secured $14M in Jun, 2026.

Who are the top competitors of Olatec?

Olatec's top competitors include Upstream Bio, Odyssey and Septerna. Among them, Trimtech Therapeutics secured the most recent funding round in June, 2026.

Olatec - 2026 Company Profile, Team, Funding & Competitors

Olatec is a series A company based in New York City (United States), founded in 2003 by Damaris Skouras. It operates as a Biopharmaceutical company developing NLRP3 antagonist therapeutics for inflammatory diseases. Olatec has raised $40M in funding from Sanders Morris Harris Group. The company has 310 active competitors, including 113 funded and 62 that have exited. Its top competitors include companies like Upstream Bio, Odyssey and Septerna.

Company Details

Biopharmaceutical company developing NLRP3 antagonist therapeutics for inflammatory diseases. It is dedicated to improving patient health through the development and commercialization of safe and effective pharmaceuticals. The company focuses on a platform of oral NLRP3 antagonist therapeutics to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by Interleukin-1 (IL-1). Their lead compound, dapansutrile, inhibits the production of pro-inflammatory cytokines. The company's platform includes multiple pharmaceutical candidates, protected by a strong portfolio of intellectual property. Their experienced management and drug development team includes international thought leaders with expertise in inflammation and immunology. The company is focused on clinical development and is committed to addressing a broad spectrum of inflammatory diseases.

Website: www.olatec.com/
Social
Email ID: *****@olatec.com

Key Metrics

Founded Year

2003

Location

New York City, United States

Stage

Series A

Total Funding

$40M in 2 rounds

Latest Funding Round

Grant (prize money), Mar 10, 2023, $*****

Investors

Sanders Morris Harris Group & 4 more

Ranked

44^th among 310 active competitors

Employee Count

14 as on Jun 30, 2026

Similar Companies

Upstream Bio & 372 more

View Olatec's full profile

Olatec has raised a total funding of $40M over 2 rounds. Its first funding round was on Feb 23, 2023. Its latest funding round was a Grant (prize money) round on Mar 10, 2023 for $*****. 1 investor participated in its latest round. Olatec has 5 institutional investors.

Here is the list of recent funding rounds of Olatec:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 10, 2023	9864299	Grant (prize money)	8884242	4472008	2522883	1394460
Feb 23, 2023	1668175	Series A	1099006	6990833	Sanders Morris Harris Group	Advection Growth Capital

Access funding benchmarks and valuations. Sign up today!

View details of Olatec's funding rounds and investors

The founders of Olatec is Damaris Skouras.

Here are the details of Olatec's key team members:

Damaris Skouras: Founder & CEO of Olatec.
Contact Info: 1 email address

View details of Olatec's Founder profiles and Board Members

Olatec's employee count trend

Olatec has 14 employees as of Jun 26. Here is Olatec's employee count trend over the years:

Uncover Olatec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Olatec include Upstream Bio, Odyssey and Septerna. Here is the list of Top 10 competitors of Olatec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Enavate Sciences & 11 others	67/100
2nd	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
3rd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
4th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
5th	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, RA Capital Management ... & 18 others	66/100
6th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, Valence Life Sciences & 11 others	64/100
7th	Trimtech Therapeutics 2023, Cambridge (United Kingdom), Seed	They develop treatments for CNS and inflammatory disorders	$47M	Cambridge Innovation Capital, SV Health Investors ... & 11 others	61/100
8th	Equillium 2017, San Diego (United States), Public	Developer of therapies for treating autoimmune and inflammatory disorders	-	ADAR1 Capital Management, Janus Henderson Investors ... & 6 others	60/100
9th	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	59/100
10th	GEn1E 2018, Palo Alto (United States), Series A	Developer of therapeutics for the treatment of inflammatory and rare diseases	$22.7M	Clear Ventures, Flucas Ventures & 7 others	59/100
44th	Olatec 2003, New York City (United States), Series A	Biopharmaceutical company developing NLRP3 antagonist therapeutics for inflammatory diseases	$40M	The Michael J. Fox Foundation, Cliffs Ventures ... & 3 others	48/100